Oculis Holding AG Ordinary shares (OCS)
Oculis Holding AG is a biomedical company focused on developing innovative ophthalmic therapies. Specializing in treatments for eye diseases, the company leverages advanced drug delivery technologies to address unmet medical needs in ophthalmology. Positioned within the pharmaceutical industry, Oculis aims to improve patient outcomes through its research and development efforts in eye care.
Company News
Oculis presented positive Phase 2 trial results for Privosegtor, showing improved visual acuity and preservation of retinal ganglion cells in acute optic neuritis patients at the ECTRIMS 2025 Congress.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan slashed the price target for Nucor Corporation (NYSE:NUE) from $190 to $180. JP Morgan analyst Bill Peterson maintained a Neutral rating. Nucor sha...
The consensus price target hints at a 152.8% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.